Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with
some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes …

Background Forty per cent of individuals with early or intermediate stage cancer and 90%
with advanced cancer have moderate to severe pain and up to 70% of patients with cancer …

Abstract CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer‐
related, namely resulting from nervous system tumor invasion, surgical nerve damage …

In addition to cancer-related death, malignant progression also leads to a series of
symptoms and side-effects, which would detrimentally affect cancer patients' the quality of …

Many genetic variants in drug metabolizing enzymes and transporters have been shown to
be relevant for treating psychiatric disorders. Associations are strong enough to feature on …

The pharmacological treatment of cancer-related pain is unsatisfactory. Tetrodotoxin (TTX)
has shown analgesia in preclinical models and clinical trials, but its clinical efficacy and …

Aims To assess and synthesize the evidence of the effects and safety of non‐
pharmacological interventions in treating pain in patients with advanced cancer …

Simple Summary This review discusses treatment approaches for providing pain relief to
oncological patients affected by pain caused by nerve damage due to the tumor, also known …

Background Cancer pain is an important and distressing symptom that tends to increase in
frequency and intensity as the cancer advances. For people with advanced cancer, the …